Villalobos, A.; Dabbous, H.H.; Little, O.; Gbolahan, O.B.; Akce, M.; Lilly, M.A.; Bercu, Z.; Kokabi, N.
Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Curr. Oncol. 2023, 30, 10100-10110.
https://doi.org/10.3390/curroncol30120734
AMA Style
Villalobos A, Dabbous HH, Little O, Gbolahan OB, Akce M, Lilly MA, Bercu Z, Kokabi N.
Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Current Oncology. 2023; 30(12):10100-10110.
https://doi.org/10.3390/curroncol30120734
Chicago/Turabian Style
Villalobos, Alexander, Howard Hussein Dabbous, Olivia Little, Olumide Babajide Gbolahan, Mehmet Akce, Meghan Allegra Lilly, Zachary Bercu, and Nima Kokabi.
2023. "Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma" Current Oncology 30, no. 12: 10100-10110.
https://doi.org/10.3390/curroncol30120734
APA Style
Villalobos, A., Dabbous, H. H., Little, O., Gbolahan, O. B., Akce, M., Lilly, M. A., Bercu, Z., & Kokabi, N.
(2023). Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma. Current Oncology, 30(12), 10100-10110.
https://doi.org/10.3390/curroncol30120734
